These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33173219)

  • 21. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
    Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
    Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
    Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
    Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of IDH mutations in acute myeloid leukemia.
    Montalban-Bravo G; DiNardo CD
    Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Author Correction: Mir142 loss unlocks IDH2
    Marshall A; Kasturiarachchi J; Datta P; Guo Y; Deltcheva E; James C; Brown J; May G; Anandagoda N; Jackson I; Howard JK; Ghazaly E; Brooks S; Khwaja A; Araki M; Araki K; Linch D; Lord GM; Enver T; Nimmo R
    Sci Rep; 2021 Mar; 11(1):6974. PubMed ID: 33753768
    [No Abstract]   [Full Text] [Related]  

  • 29. IDH2 inhibition in AML: Finally progress?
    Stein EM
    Best Pract Res Clin Haematol; 2015; 28(2-3):112-5. PubMed ID: 26590767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
    Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG
    Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
    Wang GG; Pasillas MP; Kamps MP
    Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
    Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
    Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTCF boundary remodels chromatin domain and drives aberrant
    Luo H; Wang F; Zha J; Li H; Yan B; Du Q; Yang F; Sobh A; Vulpe C; Drusbosky L; Cogle C; Chepelev I; Xu B; Nimer SD; Licht J; Qiu Y; Chen B; Xu M; Huang S
    Blood; 2018 Aug; 132(8):837-848. PubMed ID: 29760161
    [No Abstract]   [Full Text] [Related]  

  • 35. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
    Damm F; Thol F; Hollink I; Zimmermann M; Reinhardt K; van den Heuvel-Eibrink MM; Zwaan CM; de Haas V; Creutzig U; Klusmann JH; Krauter J; Heuser M; Ganser A; Reinhardt D; Thiede C
    Leukemia; 2011 Nov; 25(11):1704-10. PubMed ID: 21647152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
    Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
    BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.
    Yoshimi A; Lin KT; Wiseman DH; Rahman MA; Pastore A; Wang B; Lee SC; Micol JB; Zhang XJ; de Botton S; Penard-Lacronique V; Stein EM; Cho H; Miles RE; Inoue D; Albrecht TR; Somervaille TCP; Batta K; Amaral F; Simeoni F; Wilks DP; Cargo C; Intlekofer AM; Levine RL; Dvinge H; Bradley RK; Wagner EJ; Krainer AR; Abdel-Wahab O
    Nature; 2019 Oct; 574(7777):273-277. PubMed ID: 31578525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.